buy the dip from recent high - we are in the run-up to PDUFA as a reminder to those who apparently forgot - and approval target is $30-$40 - seems most don't understand the concept of a bullish chart - if the approval target is $30-$40 guess what the run-up rate is going to be from where we currently stand before approval?
CL: The stock has been very volatile—which is a good thing! As I tell my subscribers, my investment strategy is very simple. I buy when a stock is in the single digits; I sell when it reaches double digits. I originally bought AcelRx at a few dollars per share. I sold a portion of it when it reached $13/share. Then it dropped to $8/share, and I bought again. I sold it again when the price hit $11–12/share. Now, it is around $12/share. We shall see if it drops to a single digit again. Then I shall buy more! I hold a strong position in AcelRx and use it to trade in and out. It is still a very good buy, with lots of upside, because the FDA approval is probably worth $30–40/share. Buy low, sell high!